Showing 2461-2470 of 2656 results for "".
- The Refractive Surgery Council Rolls Out New “RSC Verified” Patient Education Program for Surgeonshttps://modernod.com/news/the-refractive-surgery-council-rolls-out-new-rsc-verified-patient-education-program-for-surgeons/2479820/Refractive surgeons who want to play a leading role in patient education and signal their commitment to quality now have a new resource: The RSC Verified program, according to The Refractive Surgery Council (RSC). The program, introduced by the RSC, opens the council’s vast library o
- CooperVision Releases Four-Year Data on Landmark MiSight 1-Day Contact Lens Studyhttps://modernod.com/news/coopervision-releases-four-year-data-on-landmark-misight-1-day-contact-lens-study/2479840/New 4-year study data shows the significant impact of a pioneering contact lens management approach to slowing the progression of myopia in children, including those whose treatment begins later. CooperVision recently presented the multi-year study’s latest outcomes during the
- ASCRS Releases Preliminary CyPass Withdrawal Consensus Statementhttps://modernod.com/news/ascrs-releases-preliminary-cypass-withdrawal-consensus-statement/2479843/The American Society of Cataract and Refractive Surgery convened a CyPass Withdrawal Task Force to review the data from the COMPASS-XT study and related research and develop an independent physician guidance document associated with the voluntary withdrawal of Alcon’s CyPass Micro-Stent. To
- Bayer, Novartis Lose Case Seeking to End NHS Use of Avastin in Wet AMDhttps://modernod.com/news/bayer-novartis-lose-case-seeking-to-end-nhs-use-of-avastin-in-wet-amd/2479853/The UK High Court on Friday ruled that 12 NHS bodies in the north-east of England can continue to use Roche’s Avastin (bevacizumab) for the treatment of wet age-related macular degeneration (AMD) after dismissing a challenge by Bayer and Novartis. In the case, Bayer and Novartis, which mark
- Alcon to Move Headquarters from Texas to Switzerland Following Proposed Spinoff From Novartishttps://modernod.com/news/alcon-to-move-headquarters-from-texas-to-switzerland-following-proposed-spinoff-from-novartis/2479901/Alcon announced plans to locate its future global headquarters in Geneva, Switzerland, following completion of its proposed spinoff from Novartis, which is expected to be completed in the first half of 2019. Alcon’s new global headquarters in Geneva will be the primary location for A
- UK Calls on Drugmakers to Stockpile 6-Week Supply of Medicines to Cope With “No Deal” Brexithttps://modernod.com/news/uk-calls-on-drugmakers-to-stockpile-6-week-supply-of-medicines-to-cope-with-no-deal-brexit/2479911/The UK’s Department of Health and Social Care has asked pharmaceutical companies that supply drugs to NHS patients to “ensure they have a minimum of six weeks additional supply” of medicines, over and above their usual buffer stocks, in case imports from the EU are disrupted in
- Ocutech Introduces New Ves Falcon Autofocus Bioptic Telescopehttps://modernod.com/news/ocutech-introduces-new-ves-falcon-autofocus-bioptic-telescope/2479963/Following 6 years of development and testing, Ocutech has introduced its new VES Falcon Autofocus Bioptic Telescope, the company’s next generation autofocusing bioptic for the visually impaired. The Falcon is in initial limited release with select low-vision specialists in the United
- Imprimis Announces Clinical Trial for Dropless TriMoxi Formulation in Canadahttps://modernod.com/news/imprimis-announces-clinical-trial-for-dropless-trimoxi-formulation-in-canada/2479968/Imprimis Pharmaceuticals announced that its Canadian partner, Advanced Dosage Forms, will begin enrolling patients at McGill University Health Centre (MUHC) for a clinical trial of Imprimis’s leading Dropless (triamcinolone acetonide-moxifloxacin) formulation aft
- EyePoint Pharmaceuticals Announces Presentation of Data Highlighting Yutiq for Posterior Segment Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-announces-presentation-of-data-highlighting-yutiq-for-posterior-segment-uveitis/2479984/EyePoint Pharmaceuticals announced the presentation of 12-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis. The data were presented at the American Society of R
- LensGen Announces Funding And Patent Successhttps://modernod.com/news/lensgen-announces-funding-and-patent-success/2480017/LensGen, a private California company developing the world’s first modular, fluid-optic, curvature changing IOL, is reporting significant progress in its effort to transform how presbyopia is addressed, according to a company news release. The company successfully achieved a key clin